生物技术公司Niagen Bioscience宣布，其候选药物NB4168用于治疗共济失调毛细血管扩张症（A-T）的研发，已获得美国食品药品监督管理局（FDA）授予的罕见儿科疾病（RPD）认定，以及欧洲药品管理局（EMA）授予的孤儿药产品（OMPD）认定。这两项认定标志着该药物在针对这一严重罕见疾病的开发进程中取得了重要监管进展。
生物技术公司Niagen Bioscience宣布，其候选药物NB4168用于治疗共济失调毛细血管扩张症（A-T）的研发，已获得美国食品药品监督管理局（FDA）授予的罕见儿科疾病（RPD）认定，以及欧洲药品管理局（EMA）授予的孤儿药产品（OMPD）认定。这两项认定标志着该药物在针对这一严重罕见疾病的开发进程中取得了重要监管进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.